NEW YORK--(BUSINESS WIRE)--The Channel Group, LLC announced today that it has formed Lesanne Life Sciences, LLC, a medical diagnostic company that is developing a simple blood test to detect the occurrence of a stroke.
Lesanne’s diagnostic test is able to detect low levels of a patented protein biomarker that is present only in the brain and related central nervous system tissue of healthy individuals. In a pilot clinical trial, the biomarker was present in blood samples obtained from stroke patients, but was not found in control patients. Pre-clinical experiments showed that the biomarker was detectable readily within 15 minutes of induction of a stroke in animal models. These findings imply that it might be possible for the first time for emergency personnel and physicians to confirm the occurrence of stroke, even before a patient is subjected to imaging. The company is developing both a qualitative blood test to be used in emergency settings for diagnosing a stroke and a quantitative blood test to be used in the hospital to monitor recovery from a stroke.
